Cinpanemab (anti-Alpha-synuclein) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab (anti-Alpha-synuclein) can be used for the research of Parkinson's disease.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg

Amyloid β-Protein Fragment 25-35 (Aβ25-35) is derived from the amyloid-β protein.amyloid-β protein, which is mapped to human chromosome 21q21.Aβ25-35 lacks the N-terminal domain and the metal binding site and is majorly generated by proteolytic cleavage

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.beta-Amyloid Peptide (12-28)(TFA salt) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein ,

Store at -20°C. Store under desiccating conditions. The product can be stored for up to 12 months.

Gantenerumab (anti-Amyloid Beta) is a fully human anti-amyloid-β (Aβ) IgG1 monoclonal antibody demonstrates sustained cerebral amyloid-β binding. Gantenerumab (anti-Amyloid Beta) can be used for Alzheimer's disease research.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg

Ponezumab (anti-Amyloid Beta) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab (anti-Amyloid Beta) reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab (anti-Amyloid

Solanezumab (anti-Amyloid Beta) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab (anti-Amyloid Beta) has the potential for the research of Alzheimer’s disease.